Billiontoone (NASDAQ:BLLN) Insider Nancy Joann Johnson Sells 3,418 Shares of Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Nancy Joann Johnson sold 3,418 shares of the stock in a transaction on Monday, June 8th. The shares were sold at an average price of $99.28, for a total transaction of $339,339.04. Following the transaction, the insider directly owned 32,482 shares in the company, valued at approximately $3,224,812.96. This represents a 9.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nancy Joann Johnson also recently made the following trade(s):

• On Tuesday, June 9th, Nancy Joann Johnson sold 10,582 shares of Billiontoone stock. The stock was sold at an average price of $100.47, for a total transaction of $1,063,173.54.

Billiontoone Stock Performance

NASDAQ BLLN opened at $99.26 on Thursday. The company has a 50-day simple moving average of $87.26 and a two-hundred day simple moving average of $88.18. Billiontoone, Inc. has a 12-month low of $61.96 and a 12-month high of $138.70. The firm has a market cap of $4.57 billion and a price-to-earnings ratio of 180.47. The company has a quick ratio of 10.58, a current ratio of 10.92 and a debt-to-equity ratio of 0.18.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.01 by $0.33. The company had revenue of $108.39 million during the quarter, compared to analysts’ expectations of $95.81 million. During the same quarter in the prior year, the firm posted ($0.39) EPS. The firm’s quarterly revenue was up 83.8% on a year-over-year basis. On average, equities analysts forecast that Billiontoone, Inc. will post 0.93 EPS for the current year.

Institutional Investors Weigh In On Billiontoone

Institutional investors and hedge funds have recently bought and sold shares of the business. Rossby Financial LCC purchased a new stake in Billiontoone in the 4th quarter worth approximately $25,000. Wells Fargo & Company MN purchased a new stake in Billiontoone in the 4th quarter worth approximately $76,000. Smartleaf Asset Management LLC purchased a new stake in Billiontoone in the 4th quarter worth approximately $80,000. Nano Cap New Millennium Growth Fund L P purchased a new stake in Billiontoone in the 4th quarter worth approximately $82,000. Finally, Renaissance Capital LLC purchased a new stake in Billiontoone in the 4th quarter worth approximately $201,000.

Analyst Ratings Changes

BLLN has been the topic of several recent research reports. Weiss Ratings lowered Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 5th. JPMorgan Chase & Co. raised their price target on Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Wall Street Zen upgraded Billiontoone from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Wells Fargo & Company reduced their price target on Billiontoone from $110.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 5th. Finally, BTIG Research reduced their price target on Billiontoone from $140.00 to $130.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Billiontoone has a consensus rating of “Moderate Buy” and an average price target of $125.29.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.